This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gruber, A. Articles by Griffin, J. H. Search for Related Content PubMed PubMed Citation Articles by Gruber, A. Articles by Griffin, J. H.

Circulation, Vol 84, 2454-2462, Copyright © 1991 by American Heart Association

ARTICLES

Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates

A Gruber, LA Harker, SR Hanson, AB Kelly and JH Griffin
Committee on Vascular Biology, Scripps Clinic and Research Foundation, La Jolla, Calif 92037.

BACKGROUND. We have determined in vivo the relative antithrombotic efficacy and hemostatic safety of combining low-dose activated protein C (APC) and urokinase (urinary plasminogen activator, u-PA), two natural proteins that regulate thrombogenesis. METHODS AND RESULTS. To model acute thrombotic responses of native blood under conditions of arterial flow, thrombogenic segments of Dacron vascular graft (VG) were incorporated into chronic exteriorized femoral arteriovenous (AV) access shunts in baboons. Thrombus formation on VG was determined by measuring 1) the deposition of autologous 111In platelets using real- time scintillation camera imaging, 2) the accumulation of 125I fibrin, 3) segment patency by Doppler flow analysis, and 4) blood tests for thrombosis, including plasma concentrations of platelet factor 4, beta- thromboglobulin, fibrinopeptide A (FPA), and D-dimer. Treatments consisting of low-dose and intermediate-dose APC (0.07 or 0.25 mg/kg.hr), u-PA (25,000 or 50,000 IU/kg.hr), or the combination were administered for 1 hour by continuous intravenous infusion. In untreated controls, platelets and fibrin accumulated rapidly, reaching plateau values at 1 hour of 15.1 +/- 3.8 x 10(9) platelets and 7.8 +/- 2.2 mg fibrin. Although the low-dose APC or u-PA alone did not decrease either platelet or fibrin deposition significantly, this combination moderately reduced both platelet and fibrin accumulation (7.3 +/- 2.6 x 10(9) platelets, p less than 0.05; 3.9 +/- 0.6 mg fibrin, p less than 0.05). Furthermore, intermediate-dose APC or u-PA reduced thrombus formation by half when administered alone (p less than 0.001 for both platelet and fibrin deposition), and the combination markedly interrupted the accumulation of platelets (3.0 +/- 1.0 x 10(9) platelets, p less than 0.001) and fibrin (1.3 +/- 0.6 mg fibrin, p less than 0.001). During active treatments, all VG segments remained patent. Hemostatic plug forming capability, as measured by template bleeding times, remained normal during all experiments (p greater than 0.05). The T50 clearance time for APC activity was not affected by the concurrent administration of u-PA. u-PA alone increased the plasma levels of D-dimer, FPA, and, interestingly, APC, implying that during pharmacological activation of the fibrinolytic system, thrombin activity was released, and the protein C pathway was activated. CONCLUSIONS. A combination of intermediate-dose APC and u-PA produce substantial and efficient antithrombotic effects without impairing hemostatic function.

This article has been cited by other articles:

				D. Ardissino, P. A. Merlini, K. A. Bauer, M. Galvani, F. Ottani, F. Franchi, F. Bertocchi, R. D. Rosenberg, and P. M. Mannucci Coagulation activation and long-term outcome in acute coronary syndromes Blood, October 15, 2003; 102(8): 2731 - 2735. [Abstract] [Full Text] [PDF]

				A. J. Gale, A. Tsavaler, and J. H. Griffin Molecular Characterization of an Extended Binding Site for Coagulation Factor Va in the Positive Exosite of Activated Protein C J. Biol. Chem., August 2, 2002; 277(32): 28836 - 28840. [Abstract] [Full Text] [PDF]

				A. J. Gale, M. J. Heeb, and J. H. Griffin The autolysis loop of activated protein C interacts with factor Va and differentiates between the Arg506 and Arg306 cleavage sites Blood, July 15, 2000; 96(2): 585 - 593. [Abstract] [Full Text] [PDF]

				J. Petaja, E. Pesonen, J. A. Fernandez, A. E. Vento, O. J. Ramo, and J. H. Griffin CARDIOPULMONARY BYPASS AND ACTIVATION OF ANTITHROMBOTIC PLASMA PROTEIN C J. Thorac. Cardiovasc. Surg., September 1, 1999; 118(3): 422 - 429. [Abstract] [Full Text] [PDF]

				R. M. Camire, M. Kalafatis, P. Simioni, A. Girolami, and P. B. Tracy Platelet-Derived Factor Va/VaLeiden Cofactor Activities Are Sustained on the Surface of Activated Platelets Despite the Presence of Activated Protein C Blood, April 15, 1998; 91(8): 2818 - 2829. [Abstract] [Full Text] [PDF]

				V. R Arruda, L. H Siquiera, L. C Chiaparini, O. R Coelho, A. P Mansur, A. Ramires, and J. M Annichino-Bizzacchi Prevalence of the prothrombin gene variant 20210 G->A among patients with myocardial infarction Cardiovasc Res, January 1, 1998; 37(1): 42 - 45. [Abstract] [Full Text] [PDF]

				K. D. Kurz, T. Smith, A. Wilson, B. Gerlitz, M. A. Richardson, and B. W. Grinnell Antithrombotic Efficacy in the Guinea Pig of a Derivative of Human Protein C With Enhanced Activation by Thrombin Blood, January 15, 1997; 89(2): 534 - 540. [Abstract] [Full Text] [PDF]